GROSSE POINTE, Mich.
- March 23, 2020
-- SciTech Development, LLC, a clinical stage biotechnology company focused on the development of cancer treatments, announced it has appointed Brian Leyland-Jones, MD, PhD as Chief Medical Officer (CMO). In this new role, Dr. Leyland-Jones will provide leadership and direction to clinical operations, clinical affairs, and assist with the Company's oncology drug development efforts.
Brian Leyland-Jones, MD, PhD is the Chief Medical Officer and Scientific Advisory Board Member for the National Foundation for Cancer Research (NFCR) and Chief Scientific Officer of The Darwin Foundation. He also serves as the Chief Medical Officer of OTraces, Xylonix and the N OF 1 Mission, collectively devoted to the implementation of prevention and cure of malignancy globally. He sits on several national and international boards including the Asian Foundation for Cancer Research (AFCR), NED Biosystems, Non-Pareil, Ratio and is Director Emeritus for the WIN Consortium. He founded Xanthus, AKESOgen and Viviphi.
SciTech's lead cancer drug, ST-001 nanoFenretinide, is comprised of nanoparticle-
sized fenretinide in a patented combination with carefully selected phospholipids. The FDA has accepted SciTech Development's IND Application for ST-001 nanoFenretinide treatment of T-cell non-Hodgkin's lymphoma (NHL). The FDA has granted Orphan Drug Status for ST-001 in the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). SciTech's product pipeline includes nanoFenretinide formulations for the treatment of several cancer indications. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | +1-313-263-4887 | firstname.lastname@example.org
SciTech Development, LLC is a clinical stage oncology drug development company currently bringing to market a proven cancer drug for diseases with otherwise limited therapeutic options. SciTech Development is headquartered in the Metropolitan Detroit, Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. Additional information regarding SciTech's nanoparticle technology and oncology drug product ST-001 nanoFenretinide is available from SciTech Development, LLC by calling +1-313-938-5517 or online at https://www.scitechdevelopment.com/